Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Eylea biosimilar injunction denial ‘negative’ for Regeneron, says UBS
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Supreme Court Should Resolve False Claims Act Causation Question
Attorney Stuart Silverman says the First Circuit’s widening the divide on the False Claims Act’s causation standard adds to the need for the Supreme Court to weigh in.
Investing1d
Regeneron stock dips as court denies Eylea patent stay
As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...
Yahoo Finance9d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due to increased competition. Please note that Regeneron co-developed Eylea with the HealthCare unit of ...
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET ...